Advaxis, Inc. Stock Nasdaq
Equities
US0076242082
Biotechnology & Medical Research
Sales 2022 | 692K 950K | Sales 2023 | 13K 17.85K | Capitalization | 7.94M 10.9M |
---|---|---|---|---|---|
Net income 2022 | -38M -52.18M | Net income 2023 | -48M -65.91M | EV / Sales 2022 * | - |
Net cash position 2022 | 657K 902K | Net Debt 2023 | 3.43M 4.72M | EV / Sales 2023 | 875 x |
P/E ratio 2022 * |
-
| P/E ratio 2023 |
-0.08
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
Managers | Title | Age | Since |
---|---|---|---|
Ken Berlin
CEO | Chief Executive Officer | 59 | 18-04-22 |
- | - | ||
- | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Sidransky
CHM | Chairman | 64 | 13-07-15 |
Roni Appel
CEO | Chief Executive Officer | 57 | 04-10-31 |
Murray Goldberg
BRD | Director/Board Member | 79 | 23-01-18 |
1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |